Skip to main content

REVIEW article

Front. Physiol.
Sec. Metabolic Physiology
Volume 15 - 2024 | doi: 10.3389/fphys.2024.1426244
This article is part of the Research Topic Strategies to Overcome Metabolic Syndrome and Related Diseases View all 10 articles

Understanding the Roles of Salt-inducible Kinases in Cardiometabolic Disease

Provisionally accepted
  • Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, United States

The final, formatted version of the article will be published soon.

    Salt-inducible kinases (SIKs) are serine/threonine kinases of the adenosine monophosphateactivated protein kinase family. Acting as mediators of a broad array of neuronal and hormonal signaling pathways, SIKs play diverse roles in many physiological and pathological processes. Phosphorylation by the upstream kinase liver kinase B1 is required for SIK activation, while phosphorylation by protein kinase A induces the binding of 14-3-3 protein and leads to SIK inhibition. SIKs are subjected to auto-phosphorylation regulation and their activity can also be modulated by Ca 2+ /calmodulin-dependent protein kinase in response to cellular calcium influx. SIKs regulate the physiological processes through direct phosphorylation on various substrates, which include class IIa histone deacetylases, cAMP-regulated transcriptional coactivators, phosphatase methylesterase-1, among others. Accumulative body of studies have demonstrated that SIKs are important regulators of the cardiovascular system, including early works establishing their roles in sodium sensing and vascular homeostasis and recent progress in pulmonary arterial hypertension and pathological cardiac remodeling. SIKs also regulate inflammation, fibrosis, and metabolic homeostasis, which are essential pathological underpinnings of cardiovascular disease. The development of small molecule SIK inhibitors provides the translational opportunity to explore their potential as therapeutic targets for treating cardiometabolic disease in the future.

    Keywords: Salt-inducible kinases, cardiovascular disease, metabolic syndrome, Inflammation, Fibrosis, SIK inhibitors

    Received: 01 May 2024; Accepted: 26 Jun 2024.

    Copyright: © 2024 Shi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Fubiao Shi, Division of Cardiovascular Medicine, Department of Medicine, Vanderbilt University Medical Center, Nashville, United States

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.